Physician profile
James Austin
NPI 1932190188
$3,964.37
in general payments reported to CMS, 2019-2025
31 companies · $513 in 2025
The $513 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $451 · 2021: $996 · 2022: $674 · 2023: $421 · 2024: $730 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,034.01 | 2020-2025 | Vraylar, Mavyret, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $886.96 | 2020-2025 | Relistor, Trulance, Xifaxan |
| Indivior INC. | $379.84 | 2019-2025 | Sublocade |
| Gilead Sciences, INC. | $301.39 | 2019-2025 | |
| Novo Nordisk INC | $140.57 | 2022-2025 | Rybelsus, Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $132.06 | 2020-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Orexo US, INC. | $122.97 | 2019-2021 | |
| Exact Sciences Corporation | $118.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $96.49 | 2020 | |
| Braeburn INC. | $89.06 | 2024-2025 | Brixadi |
| Pfizer INC. | $75.95 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $73.98 | 2019-2022 | |
| Eisai INC. | $69.87 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.27 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $63.28 | 2020-2024 | Mounjaro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $62.56 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $32.46 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $25.38 | 2021 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Corcept Therapeutics | $20.21 | 2024 | Korlym |
| Lundbeck LLC | $17.99 | 2022 | |
| Averitas Pharma INC. | $16.09 | 2024 | Qutenza |
| Mdd US Operations, LLC | $15.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.95 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.52 | 2021 | |
| Currax Pharmaceuticals LLC | $13.91 | 2024 | Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.18 | 2021 | |
| Medtronic, INC. | $12.15 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.39 | 2020 | |
| Adlon Therapeutics L.P. | $11.12 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.